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Background. Hypercalcemia is a rare but potentially dangerous complication of pediatric cancer. Of the dysgerminoma cases
reported to date, associated hypercalcemia is corrected within 2–7 days of tumor resection. Case. A 13-year-old female with
an ovarian dysgerminoma was found to be hypercalcemic on presentation. Following dysgerminoma resection, moderate
hypercaclemia persisted for 7 days and calcium remained mildly elevated for an additional 7 days. PTHrP was undetectable.
Immunolocalization studies indicated that 1α-hydroxylase was expressed in dysgerminoma tissue but 1,25(OH)2D3 was not
elevated. Conclusion. Persistently elevated calcium levels following tumor resection suggests that this case involves a previously
undescribed mechanism. Elucidation of this mechanism may oﬀer new insights into tumor biology and opportunities for
therapeutic correction of hypercalcemia in this patient population.
Copyright © 2009 Abigail Wald et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Humoral hypercalcemia of malignancy (HHM) is a rare but
potentially dangerous complication of pediatric cancer. The
incidence of pediatric malignancy-associated hypercalcemia
is between 0.4 and 1.3% [1]. Ovarian dysgerminomas,
which comprise two thirds of malignant ovarian neo-
plasms in children, are one of the most common ovarian
cancers associated with hypercalcemia. This paraneoplas-
tic disorder is usually related to tumor cell synthesis of
parathyroid hormone-related peptide (PTHrP) or 1,25-
dihydroxyvitamin D (1,25(OH)2D3) and typically resolves
within one week of tumor resection [2–4].
We report a case of hypercalcemia associated with a
dysgerminoma in which the etiology of hypercalcemia was
not determined, in spite of extensive evaluation. This case is
remarkable due to the prolonged duration of hypercalcemia
following complete surgical resection of the tumor.
2.Case
A 13-year-old female presented with a two-week history
of anorexia, fatigue, fever, emesis, abdominal pain, and
polyuria. There was no family history of endocrine neoplasia
or parathyroid disease. Physical exam was notable for a
large, ﬁrm mass extending from the pelvis to the left costal
margin. CT scan and ultrasound revealed a left ovarian
mass measuring 13 × 6.6 × 14cm without evidence of
metastases.
Initial blood work revealed an elevated total calcium
14.9mg/dL (9–10.6), normal alkaline phosphatase and albu-
min, as well as mildly elevated pancreatic enzymes. With
the exception of an elevated LDH, tumor markers associated
with ovarian cancer were normal.
To correct the hypercalcemia (and associated pancre-
atitis), aggressive ﬂuids and furosemide were administered.
After several hours, total calcium decreased to 13.4mg/dL
(ionized 1.58mmol/L). A dysgerminoma was suspected and
a left salpingo-oophorectomy was performed. As lymph
nodes were clinically suspicious, left pelvic and aortic lymph
nodes were also resected. Pathologic evaluation conﬁrmed
a left ovarian dysgerminoma with an intact capsule and
negative nodes and washings.
Postoperatively, IV ﬂuids were continued with appro-
priate diuresis. Postoperative day (POD) 1, total calcium
was 11.1mg/dL (ionized 1.56mmol/L). Unexpectedly, the2 Obstetrics and Gynecology International
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Figure 1: (a) Trend of ionized calcium after tumor resection. (b)
Immunostaining for 1 α-hydroxylase was focally positive in tumor
cell cytoplasm.
patient’s calcium began to rise (Figure 1(a)) and on POD 4,
total calcium was 14.3mg/dL (ionized 1.8mmol/L). Calcium
only stabilized (level < 12mg/dL) after furosemide was
initiated.
The persistence of hypercalcemia led to further inves-
tigation. Bone scan, SPECT, and PET imaging did not
show evidence of metastases. Immunolocalization studies
indicatedthat1α-hydroxylasewasfocallyexpressedintumor
cell cytoplasm (Figure 1(b)). Serum PTH and PTHrP were
undetectable, Vitamin 1,25-dihyroxy was 19pg/mL (15–75),
vitamin D 25-hydroxy was 23ng/mL (30–80), and urine
phosphorus and calcium were low and high, respectively. On
POD6,serumcalciumhaddecreasedtoneartheupperrange
of normal. Fuorsemide and IV ﬂuids were discontinued and
the patient was discharged. Outpatient monitoring revealed
stable calcium levels over time (Figure 1(a)).
3. Conclusion
Tumor associated hypercalcemia, not resulting from bone
marrow invasion, is termed HHM, and is caused by factors
secreted by tumors into the circulation. In most described
cases, the etiologic factor identiﬁed is PTHrP, a compound
similar to PTH, which causes increased bone resorption
and renal calcium reabsorption. Although clinically PTHrP-
induced hypercalcemia is similar to primary hyperparathy-
roidism, 1,25(OH)2D3 levels are low rather than high [2].
In the present case, low 1,25(OH)2D3 supports a PTHrP-
related mechanism of hypercalcemia, however, undetectable
PTHrP, low urine phosphorus and high urine calcium make
this mechanism unlikely.
1,25(OH)2D3 increases intestinal calcium absorption
and, along with PTH, increases calcium resorption from
bone and has been identiﬁed as another cause of HHM.
The putative mechanism is increased expression of 1 α-
hydroxylase in tumor cells and macrophages, an enzyme
that catalyzes the synthesis of 1,25(OH)2D3 [2]. In this case,
immunostainingofdysgerminomatissuefor1α-hydroxylase
was positive. Although tumor expression of 1 α-hydroxylase
is a plausible explanation, 1,25(OH)2D3 obtained on POD
1 was in the lower limits of normal making it unlikely that
increased 1 α-hydroxylase resulted in persistent hypercal-
cemia.Thehalf-lifeof1,25(OH)2D3 isshort,intherange4–6
hours, but it is theoretically possible that intracellular eﬀects
persisted after serum levels of this vitamin D metabolite
fell.
Besides PTHrP and Vitamin D, production of prost-
aglandin or cytokines by tumor or immune cells may also
play a role in HHM. These factors can increase bone
resorption by inducing osteoclasts. We cannot exclude one
of these factors or an unknown mediator contributing to the
metabolic abnormality in this case.
It is also conceivable, but unlikely, hypercalcemia was
unrelated to the dysgerminoma. Coexisting conditions
excluded were hypervitaminosis A and D, hyperparathy-
roidism, sarcoidosis, adrenal insuﬃciency, and hyperthy-
roidism.
This case is unique as moderate hypercalcemia per-
sisted 7 days following tumor resection and mild hyper-
calcemia persisted for an additional 7 days. In most
reported cases of dysgerminoma associated hypercalcemia,
calcium corrected within 2–7 days of tumor debulking
[4].
Physicians should be aware of the association between
hypercalcemia and pediatric cancer. Incomplete resolution
of hypercalcemia for over a week following tumor resection
suggestsapreviouslyundescribedmechanism.Elucidationof
this mechanism may oﬀer new insights into tumor biology
and opportunities for novel therapeutics in this patient
population.
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